01—Abstract
Summary
Summary of the 8-K filed June 6, 2025. Cited figures are marked; the original filing is the authoritative source.
On June 6, 2025, Omega Healthcare Investors, Inc. ("Omega" or the "Company") held its 2025 Annual Meeting of Stockholders, where stockholders approved an amendment to the Articles of Amendment and Restatement to increase authorized common stock, $0.10a par value per share, from 350,000,000 shares to 700,000,000 shares.
The filing states that a summary of this amendment appeared in Proposal 4 of the definitive proxy statement filed April 22, 2025, as amended, and that the full text is filed as Exhibit 3.1. Holders of 242,057,737 shares, representing approximately 84.29%b of total outstanding common stock as of the record date, were present in person or by proxy. All eight director nominees were elected, Ernst & Young LLP was ratified as independent auditor for fiscal year 2025, executive compensation was approved on an advisory basis, and the charter amendment was approved.
For the charter amendment, 231,662,341 shares voted for, 8,905,260 against, and 1,490,136 abstained. Effective upon completion of the Annual Meeting, Stephen D. Plavin was appointed to the Investment Committee in place of C.
Taylor Pickett and no longer serves on the Compensation Committee. The filing also lists the current membership of the Audit, Compensation, Investment, and Nominating and Corporate Governance Committees.
02—Key points
Key Highlights
- Stockholders approved increasing authorized common stock from 350,000,000 to 700,000,000 shares, par value $0.10 per share.
- Holders of 242,057,737 shares, approximately 84.29% of outstanding common stock as of the record date, were present or represented at the meeting.
- All eight director nominees were elected, including Kapila K. Anand, Craig R. Callen, Kevin J. Jacobs, and Burke W. Whitman.
- Ernst & Young LLP was ratified as independent auditor for fiscal year 2025, with 230,705,879 votes for and 10,808,358 against.
- Advisory vote on executive compensation passed with 190,077,014 votes for, 8,122,265 against, and 1,104,810 abstentions.
- Stephen D. Plavin was appointed to the Investment Committee, replacing C. Taylor Pickett, and left the Compensation Committee.
- Stephen D. Plavin chairs the Nominating and Corporate Governance Committee, and Craig R. Callen chairs the Investment Committee.
03—Questions
Frequently Asked Questions
Why did Omega increase its authorized common stock?
The filing states that stockholders approved the increase from 350,000,000 to 700,000,000 shares upon the unanimous recommendation of the Board of Directors. The filing refers to the proxy statement's Proposal 4 for a summary of the amendment but does not state a specific purpose in this 8-K.
How much stockholder support did the charter amendment receive?
The charter amendment received 231,662,341 votes for, 8,905,260 votes against, and 1,490,136 abstentions. The filing reports no broker non-votes for this proposal.
Did any director receive significant opposition?
All eight directors were elected. Stephen D. Plavin received the most votes against, at 10,868,304, while Kevin J. Jacobs received the most votes for, at 196,157,915. Votes against ranged from 2,718,367 for Jacobs to 10,868,304 for Plavin.
What changes were made to board committee assignments?
Effective upon completion of the Annual Meeting, Stephen D. Plavin joined the Investment Committee in place of C. Taylor Pickett and no longer serves on the Compensation Committee. The filing lists Burke W. Whitman as Compensation Committee chair and Craig R. Callen as Investment Committee chair.
04—Continue